Current Editions

With Phase II data from Alkermes and Centessa, OXR2 utility broadens. Centessa’s ORX750 appears the stronger of the two in NT2.

With nearly two dozen base editors in the clinic, the nascent technology’s potential is coming into focus

San Diego company’s physics-informed algorithms have begun delivering small molecules to the clinic in two years — and attracting partners

With RNA therapies surging and base editors advancing into the clinic, conventional CRISPR-Cas9 is facing its toughest competitive landscape yet

Tally could rise quickly as flurries of approvals common near year-end

Company’s complete response letter is a poster child for the benefits of public advisory committee meetings

In letter reiterating concerns about CNPV program, Massachusetts lawmaker outlines broader concerns

Privately held Yale spinout delivered first-in-human data for RIPTAC molecule last month, spurring deal

Investors attracted to track record, see path to returns as pharmas’ appetite for M&A remains strong

Plus: Nine-figure rounds for Solve, Artios and Aspen; and more

Nuvalent, Olema, Invivyd and Inhibikase all price offerings, as some take advantage of other companies’ news

Led the development of Oxervate to treat rare eye disease